Table 1. Patients and disease characteristics (No. 132).
| Characteristic | No. | % [range] |
|---|---|---|
| Age, median | 68 | [31–85] |
| Gender | ||
| Male/female | 87/45 | 66/34 |
| Tobacco use | ||
| Never/current/former | 12/42/75 | 9/32/57 |
| NK | 3 | 2 |
| Histology | ||
| Adenocarcinoma | 80 | 61 |
| Squamous | 35 | 27 |
| Sarcomatoid | 7 | 5 |
| Adenosquamous | 3 | 2 |
| Pleomorphic | 2 | 2 |
| Other | 5 | 4 |
| Initial stage | ||
| I/II/III | 2/3/14 | 2/2/11 |
| IV | 113 | 86 |
| Previous treatments | ||
| Surgery/NACT/RT | 7/7/5 | 5/5/4 |
| Brain metastases | 19 | 14 |
| CK-GK/ WBRT | 4/7 | 21/37 |
| Pembrolizumab | 8 | 42 |
| Steroids (on pembrolizumab) | 27 | 20 |
| ECOG PS | ||
| 0/1/2 | 42/68/22 | 32/52/17 |
| Autoimmune diseasea | 7 | 5% |
| PD-L1 expression | ||
| ≥50% (NOS) | 51 | 39 |
| 50–70%/70–80% | 32/8 | 24/6 |
| 80–90%/90–100% | 23/18 | 17/14 |
| 22C3/SP263/E1L3N | 101/22/9 | 77/17/7 |
| EGFR/ALK/ROS1 | 3/0/0 | 4b |
| Radiotherapy (metastases) | 41 | 31 |
| Response to pembrolizumab | ||
| CR/PR/SD/PD/NA | 1/55/25/36/15 | 2/42/19/27/11 |
| Discontinuation for toxicity | 14 | 11 |
| Symptomatic PD | 40 | 30 |
| Second-line | 37 | 28 |
| PR/SD/PD | 10/7/6 | 27/19/16 |
a, psoriasis in 3 (in 2 with associated arthritis), Crohn’s disease in 2, connectivities and myasthenia gravis each in one; b, of 80 patients with adenocarcinoma. CK, cyberknife; ECOG PS, Eastern Cooperative Oncology Group Performance Status; GK, gammaknife; NK, not known; No. Number; NA, not assessable; NACT, neoadjuvant chemotherapy; No., number; NOS, not otherwise specified; PD, progressive disease; PD-L1, programmed cell death-ligand-1; RT, radiotherapy; WBRT, whole brain radiotherapy.